DE60220621T2 - Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren - Google Patents

Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren Download PDF

Info

Publication number
DE60220621T2
DE60220621T2 DE60220621T DE60220621T DE60220621T2 DE 60220621 T2 DE60220621 T2 DE 60220621T2 DE 60220621 T DE60220621 T DE 60220621T DE 60220621 T DE60220621 T DE 60220621T DE 60220621 T2 DE60220621 T2 DE 60220621T2
Authority
DE
Germany
Prior art keywords
posh
polypeptide
seq
virus
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220621T
Other languages
German (de)
English (en)
Other versions
DE60220621D1 (de
Inventor
Iris Alroy
Shmuel Tuvia
Tsvika Greener
Danny Ben-Avraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Ltd
Original Assignee
Proteologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologics Inc filed Critical Proteologics Inc
Application granted granted Critical
Publication of DE60220621D1 publication Critical patent/DE60220621D1/de
Publication of DE60220621T2 publication Critical patent/DE60220621T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60220621T 2001-11-09 2002-11-11 Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren Expired - Lifetime DE60220621T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34584601P 2001-11-09 2001-11-09
US345846P 2001-11-09
US36453002P 2002-03-15 2002-03-15
US364530P 2002-03-15

Publications (2)

Publication Number Publication Date
DE60220621D1 DE60220621D1 (de) 2007-07-26
DE60220621T2 true DE60220621T2 (de) 2008-03-06

Family

ID=26994569

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220621T Expired - Lifetime DE60220621T2 (de) 2001-11-09 2002-11-11 Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren

Country Status (10)

Country Link
US (4) US7250250B2 (enExample)
EP (1) EP1310552B1 (enExample)
JP (1) JP2005519636A (enExample)
AT (1) ATE364690T1 (enExample)
AU (1) AU2002365160C1 (enExample)
CA (1) CA2465973C (enExample)
DE (1) DE60220621T2 (enExample)
IL (2) IL161764A0 (enExample)
NZ (1) NZ532908A (enExample)
WO (1) WO2003095971A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004025708D1 (de) 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
US20060188890A1 (en) * 2003-10-31 2006-08-24 Proteologics, Inc. Ubiquitin-based protein interaction assays and related compositions
JP2008517278A (ja) * 2004-10-15 2008-05-22 シグナル ファーマシューティカルズ，エルエルシー ｐ２７のユビキチン化アッセイ及びその使用方法
EP2482075A1 (en) 2004-12-01 2012-08-01 Proteologics, Ltd Ubiquitin ligase assays and related reagents
JP2008092911A (ja) * 2006-10-16 2008-04-24 Univ Of Tokyo タンパク質結合検出方法
EP2196794A4 (en) * 2007-08-30 2014-04-02 Mitsui Shipbuilding Eng DEVICE AND METHOD FOR DETECTING FLUORESCENCE ENERGY TRANSFER (FRET)
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
US9901617B2 (en) * 2013-08-14 2018-02-27 The Curators Of The University Of Missouri Cell permeable inhibitors of the scaffold protein plenty of SH3 domains (POSH) or Sh3Rfl
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
CN106754883B (zh) * 2016-12-30 2019-10-29 中山大学 一种一步、无缝、非同源、多片段的基因拼接改造方法及其试剂盒
CN112764372A (zh) * 2020-12-25 2021-05-07 天津大学 基于vpx架构的多通道信号采集系统

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008181A2 (en) * 1998-08-07 2000-02-17 Onyx Pharmaceuticals, Inc. Chp polypeptide, a ligand of pak65
WO2000022142A2 (en) * 1998-10-13 2000-04-20 Onyx Pharmaceuticals, Inc. Cell signaling polypeptides and nucleic acids
WO2000027865A1 (en) 1998-11-06 2000-05-18 The Brigham And Women's Hospital, Inc. CHARACTERIZATION OF NOVEL GENE cbl-SL
US7432049B2 (en) 2001-02-28 2008-10-07 Chondrogene Limited Compositions and methods relating to osteoarthritis
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001018542A2 (en) 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
WO2001055448A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2001238347A1 (en) 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001071042A2 (en) 2000-03-23 2001-09-27 Pe Corporation (Ny) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
US20020045170A1 (en) 2000-04-06 2002-04-18 Wong Gordon G. Polynucleotides encoding novel secreted proteins
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
EP1629082A4 (en) 2000-10-20 2009-07-22 Univ Massachusetts GENERIC CONNECTIONS AND THEIR USES OF GLUCOSE TRANSPORT
WO2003008647A2 (en) 2000-11-28 2003-01-30 University Of Cincinnati Blood assessment of injury
WO2002077235A2 (en) 2000-12-21 2002-10-03 Incyte Genomics, Inc. Intracellular signaling molecules
WO2002053719A2 (en) * 2001-01-04 2002-07-11 Incyte Genomics, Inc. Cytoskeleton-associated proteins
EP1425302A2 (en) 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US6743619B1 (en) 2001-01-30 2004-06-01 Nuvelo Nucleic acids and polypeptides
EP1383894A2 (en) * 2001-03-28 2004-01-28 Incyte Genomics, Inc. Molecules for disease detection and treatment
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002085285A2 (en) 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
CA2447357A1 (en) 2001-05-22 2002-11-28 Gene Logic, Inc. Molecular toxicology modeling
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
CA2455899A1 (en) 2001-07-31 2003-04-24 Yuval Reiss Compositions and methods for the modulation of viral maturation
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
CA2460283A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Therapeutics and diagnostics for disorders of erythropoiesis
US20030175253A1 (en) 2001-11-09 2003-09-18 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US20040096828A1 (en) * 2002-01-04 2004-05-20 Lu Dyung Aina M Cytoskeleton-associated proteins

Also Published As

Publication number Publication date
ATE364690T1 (de) 2007-07-15
EP1310552A2 (en) 2003-05-14
AU2002365160C1 (en) 2009-08-13
EP1310552B1 (en) 2007-06-13
HK1055996A1 (en) 2004-01-30
DE60220621D1 (de) 2007-07-26
US20060035213A1 (en) 2006-02-16
US7429643B2 (en) 2008-09-30
JP2005519636A (ja) 2005-07-07
WO2003095971A3 (en) 2005-04-28
IL161764A0 (en) 2005-11-20
CA2465973C (en) 2013-04-16
EP1310552A3 (en) 2003-10-08
CA2465973A1 (en) 2003-11-20
NZ532908A (en) 2008-04-30
IL161764A (en) 2010-12-30
AU2002365160A1 (en) 2003-11-11
AU2002365160B2 (en) 2008-10-30
US7250250B2 (en) 2007-07-31
US7268227B2 (en) 2007-09-11
US20060019240A1 (en) 2006-01-26
US20040025196A1 (en) 2004-02-05
WO2003095971A2 (en) 2003-11-20
US20080187538A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
US20080187538A1 (en) Posh nucleic acids, polypeptides and related methods
JP4143263B2 (ja) 治療ターゲットとしての新規ユビキチンリガーゼ
CN111904958B (zh) Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
US20070054355A1 (en) Cbl-b polypeptides, complexes and related methods
US9265788B2 (en) Compositions and methods for treatment of mitochondrial diseases
EP4638764A2 (en) Use of rtl8-deficient cells to produce biocompatible, peg10-derived virus-like particles (vlp)
US20060287337A1 (en) Trans-golgi network-associated processes, methods and compositions related thereto
US20050214751A1 (en) Inhibition of viral maturation, methods and compositions related thereto
US20070060537A1 (en) Methods and compositions for inhibiting viral infections
US20070122807A1 (en) Posh polypeptides, complexes and related methods
US20070141716A1 (en) Pem-3-like compositions and related methods thereof
Cole et al. Tetrahymena JanusA gene encodes a polo kinase whose loss triggers a dorsal/ventral intracellular homeosis
KR20190047489A (ko) 53bp1의 신규한 용도
WO2005038007A2 (en) Posh and associated proteins
WO2004098492A2 (en) Trans-golgi network-associated processes, methods and compositions related thereto
HK1055996B (en) Posh nucleic acids, polypeptides and related methods
WO2003078601A2 (en) Posh nucleic acids, polypeptides and related methods
US20070275368A1 (en) Posh Associated Kinases And Related Methods
Schöckel The dual use of cohesin and its protector Sgo1 contributes to the choreography of the chromosome and the centrosome cycle
Sanzà The role of the guanine nucleotide exchange factor Rab3GEP in the regulation of Rab27a
CHAABENE Role of associated rhoptry proteins in Toxoplasma gondii invasion
Ramabhadran Splice variation-specific cellular and biochemical function of the formin INF2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PROTEOLOGICS,LTD., REHOVOT, IL